Apellis VP granted 16,150-share stock award in Form 4

Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported an equity grant of 16,150 shares of common stock on January 28, 2026.

Rhea-AI Filing Summary

Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported an equity grant of 16,150 shares of common stock on January 28, 2026. The Form 4 shows the transaction coded as an acquisition at a price of $0 per share, tied to a restricted stock unit award.

According to the footnote, this award consists of restricted stock units that vest 25% each year over four years from the grant date, contingent on continued service. Following this grant, Chopas is shown as directly beneficially owning 65,955 shares of Apellis common stock.

Insider Trade Summary

Grant/Award: 16,150 shares

Grant/Award 1 txn

Insider Chopas James George

Role VP/Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,150	$0.00	$0.00

Holdings After Transaction: Common Stock — 65,955 shares (Direct)

Footnotes (1)

1. F1. This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Apellis (APLS) report for James George Chopas?

Apellis reported that VP and Chief Accounting Officer James George Chopas acquired 16,150 shares of common stock on January 28, 2026. The Form 4 identifies this as an equity grant at $0 per share linked to a restricted stock unit award.

How many Apellis (APLS) shares does James Chopas own after this Form 4 transaction?

After the reported transaction, James George Chopas beneficially owns 65,955 Apellis common shares directly. This figure reflects the updated total following the 16,150-share restricted stock unit-related acquisition disclosed in the January 28, 2026 Form 4 filing.

What are the vesting terms of James Chopas’s Apellis (APLS) restricted stock units?

The restricted stock unit award granted to James George Chopas on January 28, 2026 vests 25% annually over four years. Vesting is conditioned on his continued service, meaning each year one quarter of the units convert into shares if he remains employed.

Was there a purchase price for the Apellis (APLS) shares reported in this Form 4?

The Form 4 lists the transaction price as $0 per share for the 16,150 common shares acquired by James George Chopas. This reflects that the position arose from a restricted stock unit award rather than an open-market or cash purchase transaction.

What role does James George Chopas hold at Apellis (APLS) in this Form 4 filing?

James George Chopas is identified as an officer of Apellis, serving as VP and Chief Accounting Officer. The Form 4 indicates he is not a director or 10% owner, and the reported equity award relates to his status as a company officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chopas James George

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP/Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		16,150(1)	A	$0	65,955	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

	/s/ David Watson, attorney-in-fact for James Chopas	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.